Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK Cell Infusions for AML, T-ALL, and MDS
NCT02123836Phase 1Unknown
- Sponsor
- National University Hospital
- Start
- Apr 2014
- Primary completion
- Sep 2020
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of NK cell therapy (Anhui Provincial Hospital) in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS), sponsored by National University Hospital. Primary endpoint: Minimal Residual Disease at 1 year. Status: unknown.
02
Drugs
NK cell therapy (Anhui Provincial Hospital)
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02123836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02123836.